Bispecific Antibody Development

Project Snapshot — A Dubody-format bispecific antibody was recombinantly expressed, purified, and characterized through a complete QC workflow: SDS-PAGE integrity analysis, SEC-HPLC monomer purity assessment, and ELISA titer evaluation — demonstrating AtaGenix’s end-to-end bispecific antibody development capability.

Fig. 2. Dubody bispecific antibody QC by SDS-PAGE under reduced and non-reduced conditions.

Interpretation:

Clear main band with low by-products under non-reducing conditions; expected fragment bands under reducing conditions. No significant degradation or aggregation observed, indicating correct folding and stable construct design. Suitable for advanced purity and functionality evaluation.

Fig. 3. SEC-HPLC chromatogram showing main peak dominance and low aggregate fraction.

Interpretation:

Sharp, symmetrical main peak with high area ratio indicates high monomer homogeneity. Minimal aggregate and fragment peaks demonstrate good process control. High purity reduces immunogenicity and viscosity risks, supporting predictable downstream performance.

Fig. 4. ELISA titration curve showing binding strength, signal-to-noise ratio, and linear dynamic range.

Interpretation:

Signal decreases proportionally with dilution, confirming stable and reproducible binding. Left-shifted EC₅₀ indicates strong apparent affinity with a wide dynamic range. Overlapping curves across batches demonstrate reliable batch-to-batch consistency.

AtaGenix provides end-to-end bispecific antibody solutions — from recombinant expression and purification to SDS-PAGE, SEC-HPLC, and ELISA validation — enabling faster, more reliable therapeutic development.

Response within 24 hours